$157M market lost on phrasing

Posted 25 March 2025 AM

Novartis has lost its appeal to keep a $150 million drug under patent, paving the way for already-approved generics to be listed on the PBS.

The Full Court of the Federal Court has rejected the pharma's appeal filed in January against a decision that a patent term extension for the patent covering heart drug Entresto was improperly granted.

To see the whole article, please login